Tirzepatide Dual GLP-1 thiab GIP Receptor Agonist rau Kev Tswj Qhov hnyav thiab Glycemic Control
Cov lus piav qhia ntxaws
Tirzepatide yog ib qho tshuaj tshiab siv rau kev tswj qhov hnyav mus sij hawm ntev hauv cov neeg mob rog rog nrog cov neeg laus rog lossis hnyav hnyav. Nws yog glucagon-zoo li agonist ntawm glucagon polypeptide (GIP) thiab glucagon-zoo li peptide-1 (GLP-1) receptors. Pom zoo los ntawm FDA hauv xyoo 2022, tirzepatide ua ke cov teebmeem ntawm ob lub proinsulins enteric rau hauv ib lub molecule, txhim kho insulin secretion thiab txo qis glucagon. Kab lus no tshawb txog cov txheej txheem ntawm kev nqis tes ua, kev soj ntsuam kev ua tau zoo, thiab kev nyab xeeb profile ntawm tirzepatide raws li kev kho mob ntxiv rau kev poob phaus thiab txhim kho glycemic tswj hauv cov neeg mob ntshav qab zib hom 2.
I. Nkag siab Tirzepatide:
A. Glucose-dependent agonist ntawm GIP thiab GLP-1 receptors
B. Mechanism ntawm kev ua: txhim kho theem I thiab theem II kev tso tawm insulin, txo qis glucagon
II. Kev siv tshuaj kho mob thiab FDA pom zoo:
A. Kev Taw Qhia: Kev tswj qhov hnyav mus sij hawm ntev hauv cov neeg mob hnyav hnyav nrog cov neeg laus rog lossis hnyav hnyav
B. Adjunctive therapy rau kev txhim kho glycemic tswj hauv cov neeg laus uas muaj ntshav qab zib hom 2
C. FDA pom zoo thiab kev lag luam los ntawm Eli Lilly hauv 2022
III. Kev ua tau zoo hauv kev tswj qhov hnyav:
A. Comparative efficiency:
Qhov feem pua ntawm qhov hnyav poob: Cov koob tshuaj qis (5mg), koob tshuaj nruab nrab (10mg), thiab cov koob tshuaj siab (15mg)
Qhov nruab nrab qhov poob phaus feem pua ntawm cov pab pawg sib txawv
Kev sib piv nrog cov placebo pab pawg
Feem pua ntawm cov neeg kawm tau poob phaus ntau dua 20%
B. Kev nyab xeeb profile: Ntau zaus ntawm cov tshuaj tiv thaiv tsis zoo piv rau pawg placebo
C. Sib piv nrog rau lwm cov tshuaj poob phaus:
Orlistat (hauv khw muag khoom): Qhov sib txawv ntawm qhov poob phaus
IV. Mechanism ntawm Glycemic Tswj thiab yuag poob:
A. Ua kom muaj GLP-1 thiab GIP receptors
B. Kev txwv tsis pub qab los noj mov thiab txo kev noj zaub mov
Tirzepatide, raws li ib tug dual GLP-1 thiab GIP receptor agonist, muab kev tswj qhov hnyav thiab txhim kho glycemic tswj nyob rau hauv cov neeg mob rog rog nrog rau cov neeg laus rog rog los yog hnyav hnyav comorbidities, nrog rau cov neeg mob ntshav qab zib hom 2. Nws txoj kev ua haujlwm ntawm cov piam thaj-dependant txhim kho insulin secretion thiab txo cov qib glucagon. Nrog rau qhov poob phaus tseem ceeb feem pua thiab qhov kev nyab xeeb muaj txiaj ntsig zoo, tirzepatide sawv tawm raws li cov tshuaj muaj zog rau kev tswj qhov hnyav mus ntev. Kev tshawb fawb ntxiv thiab kev tshawb fawb soj ntsuam yuav txuas ntxiv tshawb nrhiav cov txiaj ntsig zoo thiab kev siv ntawm cov tshuaj cog lus no.
Txhawm rau muab kev lag luam zoo dua, peb tuaj yeem kho cov tshuaj ntsiav thiab cov khoom ua kua, raws li koj cov khoom xyaw.
Peb tuaj yeem kho qhov ntau npaum li cas: 500mg / capsule, 550mg / capsule, 600mg / capsule.
Peb tuaj yeem kho qhov ntim: 60 lub kaus mom / lub raj mis, 90 lub kaus mom / lub raj mis, 120 lub kaus mom / lub raj mis.
Peb tuaj yeem hloov kho cov plhaub thiab cov xim: cog cov kaus poom, gelatin capsule plhaub.
Specification
